{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:43:37Z","timestamp":1789771417888,"version":"4.0.1"},"reference-count":35,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.1620\/tjem.231.21","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T23:14:02Z","timestamp":1377904442000},"page":"21-28","source":"Crossref","is-referenced-by-count":17,"title":["Better Outcome of XELOX Chemotherapy in Patients with Advanced Intestinal-Type Adenocarcinoma of the Ampulla of Vater"],"prefix":"10.1620","volume":"231","author":[{"given":"Han Sang","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunki","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","unstructured":"Agaram, N.P., Shia, J., Tang, L.H. &amp; Klimstra, D.S. (2010) DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases. <i>Am. J. Clin. Pathol.<\/i>, 133, 772-780."},{"key":"2","unstructured":"Amptoulach, S., Josefsson, A., Kavantzas, N. &amp; Kalaitzakis, E. (2011) Adenocarcinoma of the ampulla of Vater: does the histopathologic type matter? <i>Scand. J. Gastroenterol.<\/i>, 46, 1401-1403."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Andre, T., Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F., Avenin, D., Selle, F., Paye, F., Hannoun, L., Houry, S., Gayet, B., Lotz, J.P., de Gramont, A. &amp; Louvet, C. (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. <i>Ann. Oncol.<\/i>, 15, 1339-1343.","DOI":"10.1093\/annonc\/mdh351"},{"key":"4","unstructured":"Carter, J.T., Grenert, J.P., Rubenstein, L., Stewart, L. &amp; Way, L.W. (2008) Tumors of the ampulla of vater: histopathologic classification and predictors of survival. <i>J. Am. Coll. Surg.<\/i>, 207, 210-218."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., Schoffski, P., Sobrero, A., Van Cutsem, E. &amp; Diaz-Rubio, E. (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. <i>J. Clin. Oncol.<\/i>, 22, 2084-2091.","DOI":"10.1200\/JCO.2004.11.069"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Cereda, S., Passoni, P., Reni, M., Vigano, M.G., Aldrighetti, L., Nicoletti, R. &amp; Villa, E. (2010) The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. <i>Cancer<\/i>, 116, 2208-2214.","DOI":"10.1002\/cncr.24970"},{"key":"7","unstructured":"Chu, P.G., Schwarz, R.E., Lau, S.K., Yen, Y. &amp; Weiss, L.M. (2005) Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. <i>Am. J. Surg. Pathol.<\/i>, 29, 359-367."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cunningham, D., Atkin, W., Lenz, H.J., Lynch, H.T., Minsky, B., Nordlinger, B. &amp; Starling, N. (2010) Colorectal cancer. <i>Lancet<\/i>, 375, 1030-1047.","DOI":"10.1016\/S0140-6736(10)60353-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"de Castro, S.M., van Heek, N.T., Kuhlmann, K.F., Busch, O.R., Offerhaus, G.J., van Gulik, T.M., Obertop, H. &amp; Gouma, D.J. (2004) Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. <i> Surgery<\/i>, 136, 994-1002.","DOI":"10.1016\/j.surg.2004.03.010"},{"key":"10","unstructured":"Fischer, H.P. &amp; Zhou, H. (2004) Pathogenesis of carcinoma of the papilla of Vater. <i>J. Hepatobiliary Pancreat. Surg.<\/i>, 11, 301-309."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Gibson, M.K., Holcroft, C.A., Kvols, L.K. &amp; Haller, D. (2005) Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. <i>Oncologist<\/i>, 10, 132-137.","DOI":"10.1634\/theoncologist.10-2-132"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hansel, D.E., Maitra, A., Lin, J.W., Goggins, M., Argani, P., Yeo, C.J., Piantadosi, S., Leach, S.D. &amp; Biankin, A.V. (2005) Expression of the caudal-type homeodomain transcription factors CDX 1\/2 and outcome in carcinomas of the ampulla of Vater. <i>J. Clin. Oncol.<\/i>, 23, 1811-1818.","DOI":"10.1200\/JCO.2005.03.068"},{"key":"13","unstructured":"Heinrich, S. &amp; Clavien, P.A. (2010) Ampullary cancer. <i>Curr. Opin. Gastroenterol.<\/i>, 26, 280-285."},{"key":"14","unstructured":"Howe, J.R., Klimstra, D.S., Cordon-Cardo, C., Paty, P.B., Park, P.Y. &amp; Brennan, M.F. (1997) K-ras mutation in adenomas and carcinomas of the ampulla of vater. <i>Clin. Cancer Res.<\/i>, 3, 129-133."},{"key":"15","unstructured":"Howe, J.R., Klimstra, D.S., Moccia, R.D., Conlon, K.C. &amp; Brennan, M.F. (1998) Factors predictive of survival in ampullary carcinoma. <i>Ann. Surg.<\/i>, 228, 87-94."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Jatoi, A., Murphy, B.R., Foster, N.R., Nikcevich, D.A., Alberts, S.R., Knost, J.A., Fitch, T.R. &amp; Rowland, K.M. Jr. (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. <i>Ann. Oncol.<\/i>, 17, 29-34.","DOI":"10.1093\/annonc\/mdj063"},{"key":"17","unstructured":"Kim, G.M., Jeung, H.C., Rha, S.Y., Kim, H.S., Jung, I., Nam, B.H., Lee, K.H. &amp; Chung, H.C. (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. <i>Eur. J. Cancer<\/i>, 48, 518-526."},{"key":"18","unstructured":"Kim, S.T., Lee, J., Lee, K.T., Lee, J.K., Lee, K.H., Choi, S.H., Heo, J.S., Choi, D.W., Park, S.H., Park, J.O., Lim, H.Y., Park, Y.S. &amp; Kang, W.K. (2010) The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. <i>Med. Oncol.<\/i>, 27, 1149-1154."},{"key":"19","unstructured":"Kimura, W., Futakawa, N., Yamagata, S., Wada, Y., Kuroda, A., Muto, T. &amp; Esaki, Y. (1994) Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. <i>Jpn. J. Cancer Res.<\/i>, 85, 161-166."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lee, J., Park, S.H., Chang, H.M., Kim, J.S., Choi, H.J., Lee, M.A., Jang, J.S., Jeung, H.C., Kang, J.H., Lee, H.W., Shin, D.B., Kang, H.J., Sun, J.M., Park, J.O., Park, Y.S., Kang, W.K. &amp; Lim, H.Y. (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncol.<\/i>, 13, 181-188.","DOI":"10.1016\/S1470-2045(11)70301-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Lowe, M.C., Coban, I., Adsay, N.V., Sarmiento, J.M., Chu, C.K., Staley, C.A., Galloway, J.R. &amp; Kooby, D.A. (2009) Important prognostic factors in adenocarcinoma of the ampulla of Vater. <i>Am. Surg.<\/i>, 75, 754-760; discussion 761.","DOI":"10.1177\/000313480907500904"},{"key":"22","unstructured":"Monson, J.R., Donohue, J.H., McEntee, G.P., McIlrath, D.C., van Heerden, J.A., Shorter, R.G., Nagorney, D.M. &amp; Ilstrup, D.M. (1991) Radical resection for carcinoma of the ampulla of Vater. <i>Arch. Surg.<\/i>, 126, 353-357."},{"key":"23","unstructured":"Overman, M.J., Varadhachary, G.R., Kopetz, S., Adinin, R., Lin, E., Morris, J.S., Eng, C., Abbruzzese, J.L. &amp; Wolff, R.A. (2009) Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>J. Clin. Oncol.<\/i>, 27, 2598-2603."},{"key":"24","doi-asserted-by":"crossref","unstructured":"Perrone, G., Santini, D., Zagami, M., Vincenzi, B., Verzi, A., Morini, S., Borzomati, D., Coppola, R., Antinori, A., Magistrelli, P., Tonini, G. &amp; Rabitti, C. (2006) COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. <i>Virchows Arch.<\/i>, 449, 334-340.","DOI":"10.1007\/s00428-006-0255-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Rao, S., Cunningham, D., Hawkins, R.E., Hill, M.E., Smith, D., Daniel, F., Ross, P.J., Oates, J. &amp; Norman, A.R. (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. <i>Br. J. Cancer<\/i>, 92, 1650-1654.","DOI":"10.1038\/sj.bjc.6602576"},{"key":"26","unstructured":"Romiti, A., Barucca, V., Zullo, A., Sarcina, I., Di Rocco, R., D\u2019Antonio, C., Latorre, M. &amp; Marchetti, P. (2012) Tumors of ampulla of Vater: a case series and review of chemotherapy options. <i>World J. Gastrointest. Oncol.<\/i>, 4, 60-67."},{"key":"27","unstructured":"Ruemmele, P., Dietmaier, W., Terracciano, L., Tornillo, L., Bataille, F., Kaiser, A., Wuensch, P.H., Heinmoeller, E., Homayounfar, K., Luettges, J., Kloeppel, G., Sessa, F., Edmonston, T.B., Schneider-Stock, R., Klinkhammer-Schalke, M., Pauer, A., Schick, S., Hofstaedter, F., Baumhoer, D. &amp; Hartmann, A. (2009) Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. <i>Am. J. Surg. Pathol.<\/i>, 33, 691-704."},{"key":"28","doi-asserted-by":"crossref","unstructured":"Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.S., Rivera, F., Couture, F., Sirzen, F. &amp; Cassidy, J. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>J. Clin. Oncol.<\/i>, 26, 2013-2019.","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Sessa, F., Furlan, D., Zampatti, C., Carnevali, I., Franzi, F. &amp; Capella, C. (2007) Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. <i>Virchows Arch.<\/i>, 451, 649-657.","DOI":"10.1007\/s00428-007-0444-1"},{"key":"30","unstructured":"Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S.P., Roughton, M. &amp; Bridgewater, J. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. <i>N. Engl. J. Med.<\/i>, 362, 1273-1281."},{"key":"31","doi-asserted-by":"crossref","unstructured":"Westgaard, A., Pomianowska, E., Clausen, O.P. &amp; Gladhaug, I.P. (2013) Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? <i>Ann. Surg. Oncol.<\/i>, 20, 430-439.","DOI":"10.1245\/s10434-012-2603-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Westgaard, A., Schjolberg, A.R., Cvancarova, M., Eide, T.J., Clausen, O.P. &amp; Gladhaug, I.P. (2009) Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. <i>Histopathology<\/i>, 54, 337-347.","DOI":"10.1111\/j.1365-2559.2009.03227.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Westgaard, A., Tafjord, S., Farstad, I.N., Cvancarova, M., Eide, T.J., Mathisen, O., Clausen, O.P. &amp; Gladhaug, I.P. (2008) Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. <i>BMC Cancer<\/i>, 8, 170.","DOI":"10.1186\/1471-2407-8-170"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Woo, S.M., Ryu, J.K., Lee, S.H., Yoo, J.W., Park, J.K., Kim, Y.T., Jang, J.Y., Kim, S.W., Kang, G.H. &amp; Yoon, Y.B. (2007) Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. <i>Ann. Surg. Oncol.<\/i>, 14, 3195-3201.","DOI":"10.1245\/s10434-007-9537-y"},{"key":"35","unstructured":"Zhou, H., Schaefer, N., Wolff, M. &amp; Fischer, H.P. (2004) Carcinoma of the ampulla of Vater: comparative histologic\/immunohistochemical classification and follow-up. <i> Am. J. Surg. Pathol.<\/i>, 28, 875-882."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/231\/1\/231_21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T08:56:27Z","timestamp":1646470587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/231\/1\/231_21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.231.21","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}